3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Uterine Cervical Neoplasms
1
Tongue Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
10
Cetuximab
7
Radiotherapy, Intensity-Modulated
5
Radiotherapy
4
Docetaxel
3
Sorafenib
2
Paclitaxel
2
Fluorouracil
2
Erlotinib Hydrochloride
2
Celecoxib
2
temsirolimus
1
saracatinib
1
ixabepilone
1
cediranib
1
adavosertib
1
Zinc Oxide
1
Vorinostat
1
Vaccinium myrtillus extract
1
Trioxsalen
1
Taxes
1
Standard of Care
1
Soybean Proteins
1
Sirolimus
1
Ritonavir
1
Practice Guidelines as Topic
1
Platinum
1
Phototherapy
1
Photochemotherapy
1
Observation
1
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Tongue Neoplasms
×
DMAC2L protein, human
×
Clear all
NCT02748707
2022-04-28
ERLO-XIB
Tata Memorial Hospital
Phase 2
Unknown
64 enrolled